CML patients are ordered by BCR::ABL1IS (%) following 12 months of TKI therapy (M12) and retrospectively stratified as per European LeukemiaNet recommendations; Optimal = CML1-4 (≤0.1%), Warning = CML5-7 (>0.1–1%), Failure = CML8-9 (>1 %). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.